This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.PrimaryDetermine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362.Secondary1. Determine the overall rates and risk factors (e.g. triglycerides,cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke.2. Compare the time to development of AIDS-defining complications andserious infections or cardiovascular disease in subjects who were assignedto receive Azithromycin to those who were assigned to receive placebo.3. Evaluate the association between CD4 counts and HIV RNA levels atbaseline and during follow-up and risk of opportunistic infections and otherHIV-related complications.4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo.5. Define the risk of cognitive deterioration in a cohort of patients whohave been severely immunosuppressed and recovered CD4 counts while takingHighly Active Antiretroviral Therapy (HAART).6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated withcognitive decline.7. Evaluate factors associated with long-term adherence to antiretroviralmedications and the effect of adherence on viral suppression over time andon the development of opportunistic and serious bacterial infections andcardiovascular diseas
Showing the most recent 10 out of 589 publications